https://prabadinews.com/
administrator

FDA Rationale for Breakpoints Recognition Decision: Azithromycin and Neisseria gonorrhoeae

FDA Rationale for Breakpoints Recognition Decision: Azithromycin and Neisseria gonorrhoeae

Non-Pharmaceutical Interventions Can Disrupt Dynamics of Pneumococcal Disease

The implementation of non-pharmaceutical measures during the COVID-19 pandemic reduced transmission of Streptococcus pneumoniae, a key bacterium that causes pneumococcal…

American Academy of Pediatrics Releases 2025 Child, Adolescent Immunization Recommendations

The AAP unveiled its 2025 immunization schedule, challenging CDC guidelines and emphasizing evidence-based vaccine recommendations for children’s health.

A Deep Dive Into the Announcements at Epic UGM 2025

If you’re on LinkedIn and you work in health IT, then you’ve certainly seen everyone sharing their thoughts, perspectives, and…

Advancing Breast Cancer Care: The Role of Palbociclib in HR+/HER2- Disease

Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.

Snickers maker Mars pursues stable chocolate supply with gene-editing

The candy giant is using Pairwise’s plant-breeding technology to improve cocoa production as climate challenges and disease send prices soaring.

White House data sharing plan boasts big ambitions, but has scant details

Improving health data exchange is a worthy goal, but the initiative so far includes few details on how it will…

Amazon’s 2025 peak season fulfillment fees match last year’s rates

The e-commerce giant didn’t elaborate on the pricing decision, but the company has made strides in lowering its cost to…

Why Attackers Are Still Phishing for Patient Data in Healthcare

The following is a guest article by Gerasim Hovhannisyan, CEO at EasyDMARC In just the first six months of 2025,…

Probiotic Supplementation in Very-Low-Birth-Weight Preterm Infants Lowers Gut Antibiotic Resistance

Probiotic supplementation in VLBW preterm infants reduces antibiotic resistance and promotes beneficial gut bacteria, enhancing neonatal health outcomes.